Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Covigenix VAX 001

Next Previous
Drug Profile

Covigenix VAX 001

Alternative Names: COVID-19 DNA vaccine - Entos Pharmaceuticals; COVID-2019 DNA vaccine - Entos Pharmaceuticals; Covigenix VAX-001; SARS-COV-2 vaccine - Entos Pharmaceuticals

Latest Information Update: 01 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Entos Pharmaceuticals
  • Class COVID-19 vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Phase I/II COVID 2019 infections

Most Recent Events

  • 06 Dec 2023 Entos Pharmaceuticals completes a phase-I/II trial in COVID-2019 infections (Prevention) in Burkina Faso, Canada, Senegal and South Africa (IM) (NCT04591184)
  • 30 Sep 2022 Entos Pharmaceuticals completes enrollment in its phase-II clinical trial in COVID-2019 infections (Prevention, In adults, In the elderly) in Burkina Faso (IM) (NCT04591184)
  • 02 Sep 2021 Entos Pharmaceuticals receives approval from the South African Health Products Regulatory Authority (SAHPRA) to initiate a phase II clinical trial of covigenix VAX 001 in COVID-2019 infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top